Search Our Publications and Tools

  1. Current Utilization of Second- and Third-Line Therapies in Patients with Type 2 Diabetes

    COMPUS Reports

    August 10, 2010

    View Report

  2. Second-Line Therapy for Patients With Diabetes Inadequately Controlled on Metformin: A Systematic Review and Cost-Effectiveness Analysis

    COMPUS Reports

    August 4, 2010

    View Report

  3. Optimal Therapy Recommendations for the Prescribing and Use of Second-Line Therapy for Patients with Diabetes Inadequately Controlled on Metformin

    COMPUS Reports

    August 4, 2010

    View Report

  4. Using Evidence in the Real World

    COMPUS Reports

    March 29, 2010

    View Tool “Using Evidence in the Real World” is a didactic presentation that provides a basic overview of evidence-based decision making, using CADTH's work on self-monitoring of blood glucose and insulin analogues as examples. ...

    View Summary

  5. Guide to Starting and Adjusting Insulin for Type 2 Diabetes

    COMPUS Reports

    March 29, 2010

    View Tool The Guide to Starting and Adjusting Insulin for Type 2 Diabetes is a fold out information card providing health care professionals with guidance on how and when to start insulin....

    View Summary

  6. Current Practice Analysis of Health Care Providers and Patients: Second-line Therapy for Patients With Type 2 Diabetes Inadequately Controlled on Metformin

    COMPUS Reports

    March 12, 2010

    View Report

  7. SUMMARY REPORT: Optimal Prescribing and Use of Blood Glucose Test Strips for Self-Monitoring of Blood Glucose

    COMPUS Reports

    December 8, 2009

    The Canadian Agency for Drugs and Technologies in Health (CADTH) ― through its Canadian Optimal Medication Prescribing and Utilization Service (COMPUS) — has released a series of Optimal Therapy Reports on the self-monitoring of blood glucose (SMBG), together with recommendations and int...

    View Summary View Report

  8. Gap Analysis and Key Messages for the Prescribing and Use of Blood Glucose Test Strips for the Self-Monitoring of Blood Glucose

    COMPUS Reports

    November 12, 2009

    View Report

  9. COMPUS Diabetes Project — Optimal Self-Monitoring of Blood Glucose: PROJECT IN BRIEF

    COMPUS Reports

    November 12, 2009

    View Report

  10. Optimal Therapy Recommendations for the Prescribing and Use of Blood Glucose Test Strips

    COMPUS Reports

    July 28, 2009

    View Report

  11. Second-Line Therapy for Patients with Diabetes Inadequately Controlled on Metformin — PROJECT PROTOCOL

    COMPUS Reports

    July 28, 2009

    View Report

  12. Cost-Effectiveness of Blood Glucose Test Strips in the Management of Adult Patients with Diabetes Mellitus

    COMPUS Reports

    May 15, 2009

    View Report

  13. Systematic Review of Use of Blood Glucose Test Strips for the Management of Diabetes Mellitus

    COMPUS Reports

    May 15, 2009

    View Report

  14. SUMMARY REPORT: Optimal Prescribing and Use of Insulin Analogues

    COMPUS Reports

    March 31, 2009

    View Report

  15. Academic Detailing Upskilling Document – Insulin Analogues

    COMPUS Reports

    March 31, 2009

    View Report

  16. Didactic Presentation for Pharmacists

    COMPUS Reports

    March 31, 2009

    View Report

  17. Interactive Case Studies

    COMPUS Reports

    March 31, 2009

    View Report

  18. Current Practice Analysis of Health Care Providers and Patients on Self- Monitoring of Blood Glucose

    COMPUS Reports

    March 27, 2009

    View Report

  19. Current Utilization of Blood Glucose Test Strips in Canada

    COMPUS Reports

    March 9, 2009

    View Report

  20. INSULIN MANAGEMENT: Evidence, Tips & Pearls

    COMPUS Reports

    March 9, 2009

    View Report

  21. Gap Analysis and Key Messages for the Prescribing and Use of Insulin Analogues

    COMPUS Reports

    January 20, 2009

    This report is prepared by the Canadian Optimal Medication Prescribing and Utilization Service (COMPUS), a service of the Canadian Agency for Drugs and Technologies in Health (CADTH). This report is based on the comparison of evidence-based recommendations related to the prescribing and use of insul...

    View Summary View Report

  22. Optimal Therapy Recommendations for the Prescribing and Use of Insulin Analogues

    COMPUS Reports

    January 20, 2009

    This report is based on comprehensive meta-analyses — Long-Acting Insulin Analogues for the Treatment of Diabetes Mellitus: Meta-analyses of Clinical Outcomes, Update of CADTH Technology Report No. 92; and Rapid-Acting Insulin Analogues for the Treatment of Diabetes Mellitus: Meta-analyses of ...

    View Summary View Report

  23. Use of Blood Glucose Test Strips for the Management of Diabetes Mellitus – PROJECT PROTOCOL

    COMPUS Reports

    October 15, 2008

    This report has been prepared by the Canadian Optimal Medication Prescribing and Utilization Service (COMPUS), a service of the Canadian Agency for Drugs and Technologies in Health (CADTH). It contains a comprehensive review of existing public literature, studies, materials, and other information an...

    View Summary View Report

  24. Evaluation Framework

    COMPUS Reports

    May 15, 2008

    The Canadian Optimal Medication Prescribing and Utilization Service (COMPUS) is producing a collection of intervention tools to disseminate its key messages on proton pump inhibitors (PPIs). The following tools are being developed in collaboration with experts in continuing professional development...

    View Summary View Report

  25. Alternative Prescription Pad

    COMPUS Reports

    April 15, 2008

    View Report

  26. Long-acting insulin analogues for the treatment of diabetes mellitus:

    COMPUS Reports

    March 25, 2008

    Most studies of the long-acting insulin analogues were of poor quality and were not designed to measure differences in clinically important outcomes. There is no evidence that IGlar offers benefit over NPH insulin in children with type 1 DM, although IDet may have benefits in terms of reduced noc...

    View Summary View Report

  27. An economic evaluation of insulin analogues for the treatment

    COMPUS Reports

    March 25, 2008

    The objective of this economic assessment was to determine the cost-effectiveness of using IAs in the management of T1DM and T2DM, compared to HIs, in Canada. The results of this analysis may assist those who are responsible for making informed judgments on the reimbursement and prescribing of IAs f...

    View Summary View Report

  28. Current utilization of insulin products in Canada

    COMPUS Reports

    March 1, 2008

    To identify and promote the implementation of evidence-based and cost-effective optimal therapy in the prescribing and use of long and rapid-acting insulin analogues, COMPUS followed the process outlined in the flow chart to the right. This report represents Current Utilization Analysis step....

    View Summary View Report

  29. Rapid-acting insulin analogues for the treatment of diabetes mellitus: meta-analyses of clinical outcomes

    COMPUS Reports

    January 15, 2008

    The bulk of the available evidence on rapid-acting insulin analogues for both type 1 and type 2 diabetes consists of short- to medium-term comparisons with HI in terms of A1c and hypoglycemia. Most studies were of poor methodological quality. Based on the available evidence, the benefit of rapid...

    View Summary View Report

  30. GRADE evidence profiles on long and rapid acting insulin analogues for the treatment of diabetes mellitus

    COMPUS Reports

    January 15, 2008

    The Canadian Optimal Medication Prescribing and Utilization Service (COMPUS) has applied the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach to its work. The GRADE approach was developed to assist recommendation-making groups in making judgments about the qualit...

    View Summary View Report

  31. Current practice analysis: insulin analogues. A qualitative analysis of Canadian physician perceptions and use of insulin analogues

    COMPUS Reports

    January 1, 2008

    For less than a decade, insulin analogues have been available to be used in combination with, or as replacements for, human insulins, providing new treatment options with type 1 or type 2 diabetes. Several recent reviews of randomized controlled trials comparing regular human and analogue insuli...

    View Summary View Report

  32. Physician Self-Audit Tool

    COMPUS Reports

    September 1, 2007

    The Canadian Optimal Medication Prescribing and Utilization Service (COMPUS) self-audit tool is intended as a template and may be customized to suit the requirements of the distributor (provincial jurisdictions or continuing education providers, for example). The information collected enables the di...

    View Summary View Report

  33. Upskilling Document

    COMPUS Reports

    April 15, 2007

    The academic detailing upskilling document on proton pump inhibitors is intended as a companion document to the Canadian Agency for Drugs and Technologies in Health’s (CADTH’s) Scientific Report entitled, Evidence for PPI Use in Gastroesophageal Reflux Disease, Dyspepsia and Peptic Ul...

    View Summary View Report

  34. Academic Detailing Newsletter

    COMPUS Reports

    April 15, 2007

    Optimal Therapy Newsletter: Proton Pump Inhibitors...

    View Summary View Report

  35. COMPUS/RxFiles Pearls Document

    COMPUS Reports

    April 15, 2007

    OBJECTIVE COMPARATIVE DRUG INFORMATION & EDUCATION RxFiles Academic Detailing Program Saskatchewan’s Academic Detailing Program...

    View Summary View Report

  36. Economic models and conclusions for the treatment of dyspepsia; and gastroesophageal reflux disease – related heartburn and the prevention of non-steroidal anti-inflammatory drug-induced gastrointestinal complications.

    COMPUS Reports

    April 1, 2007

    The clinical and economic evidence for the treatment of common GI ailments (i.e., uninvestigated GERD, uninvestigated dyspepsia, and NSAID ulcer = prophylaxis) in the general practice setting suggests that PPIs (at a price equal to or less than $1.25 per day) may be cost-effective depending on thewi...

    View Summary View Report

  37. Presentation for Pharmacists - Proton Pump Inhibitors and the Treatment

    COMPUS Reports

    April 1, 2007

    Presentation for Pharmacists...

    View Summary View Report

  38. Quick Reference Prescribing Aid

    COMPUS Reports

    April 1, 2007

    View Report

  39. Proton Pump Inhibitor Project Overview: Executive Summary

    COMPUS Reports

    March 15, 2007

    This Executive Summary is based on a comprehensive Scientific Report (Optimal Therapy Report – COMPUS: Evidence for PPI use in gastroesophageal reflux disease, dyspepsia and peptic ulcer disease: scientific report) and economic report on the topic, prepared by the Canadian Optimal Medicatio...

    View Summary View Report

  40. Evidence for PPI use in gastroesophageal reflux disease, dyspepsia and peptic ulcer disease: scientific report

    COMPUS Reports

    March 15, 2007

    1. ISSUE The Canadian Optimal Medication Prescribing and Utilization Service (COMPUS) was tasked by the federal, provincial, and territorial ministries of health to identify and promote the implementation of evidence-based and cost-effective optimal therapy in the prescribing and use of proton ...

    View Summary View Report

  41. Current practice analysis report for the prescribing and use of proton pump inhibitors

    COMPUS Reports

    March 15, 2007

    The purpose of this report is to foster an understanding of how proton pump inhibitors (PPIs) are being prescribed and used in Canada. It is critical to have a clear picture of the current practice in Canada regarding PPIs so that gaps between the current practice and the optimal prescribing and use...

    View Summary View Report

  42. Project in Brief - The COMPUS PPI Project – From Evidence to Interventions to Improved Health Outcomes

    COMPUS Reports

    March 15, 2007

    Key Messages All PPIs are equally efficacious in the initial treatment of GERD, dyspepsia and other common GI conditions. Doubling the standard daily doses of PPIs, as initial therapy, is no better than standard daily dose therapy. PPIs are not efficacious in treating cough, asthma or laryngeal...

    View Summary View Report

  43. Interventions for appropriate prescribing of proton pump inhibitors: a literature review

    COMPUS Reports

    March 1, 2007

    The studies in the review suggest that combining educational multifaceted interventions that involve both professionals and patients with policy intervention may encourage appropriate prescribing and use of proton pump inhibitors. However, the decision on the selection of interventions should be tai...

    View Summary View Report

  44. Gap analysis report for the prescribing and use of proton pump inhibitors

    COMPUS Reports

    March 1, 2007

    The purpose of this report is to identify gaps in the current prescribing and use of PPIs. This document presents three gaps in the use of PPIs as determined by a review of current practice in the prescribing and use of PPIs in Canada compared with the Evidence Statements contained in theScienti...

    View Summary View Report

  45. Selection of interventions report: PPI project

    COMPUS Reports

    March 1, 2007

    The intent of this report is to identify a variety of interventions that would be best suited to optimizing the prescribing and use of proton pump inhibitors in different settings. While CADTH has taken care in the preparation of the report to ensure that its contents are accurate, complete and ...

    View Summary View Report

  46. Proton Pump Inhibitor Project Overview: Summaries

    COMPUS Reports

    March 1, 2007

    This Executive Summary is based on a comprehensive Scientific Report (Optimal Therapy Report – COMPUS: Evidence for PPI use in gastroesophageal reflux disease, dyspepsia and peptic ulcer disease [Scientific Report]) and economic report on the topic, prepared by the Canadian Optimal Medication ...

    View Summary View Report

  47. Didactic Presentation for Pharmacists

    COMPUS Reports

    February 1, 2007

    View Report

  48. Didactic Presentation for Physicians

    COMPUS Reports

    February 1, 2007

    View Report

  49. Interactive Presentation for Physicians

    COMPUS Reports

    February 1, 2007

    View Report